产品
编 号：F755159
分子式：C34H33N5O7
分子量：623.66
分子式：C34H33N5O7
分子量：623.66
产品类型
规格
价格
是否有货
结构图
CAS No: 2740495-53-6
产品详情
生物活性：
c-Met/HDAC-IN-2 is a highly potent c-Met and HDAC dual inhibitor with IC50s of 18.49 nM and 5.40 nM for HDAC1 and c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance.
体外研究：
c-Met/HDAC-IN-2 (compound 14X) (0-20 μM; 72 hours) exhibits antiproliferative activities against HCT-116, MCF-7 and A549.c-Met/HDAC-IN-2 (0.2-5 μM; 48 hours) induces of cancer cell apoptosis in a dose-dependent manner.c-Met/HDAC-IN-2 (0.2-5 μM; 48 hours) significantly causes G2/M-phase arrest in HCT-116 cells in a dose dependent manner.
c-Met/HDAC-IN-2 is a highly potent c-Met and HDAC dual inhibitor with IC50s of 18.49 nM and 5.40 nM for HDAC1 and c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance.
体外研究：
c-Met/HDAC-IN-2 (compound 14X) (0-20 μM; 72 hours) exhibits antiproliferative activities against HCT-116, MCF-7 and A549.c-Met/HDAC-IN-2 (0.2-5 μM; 48 hours) induces of cancer cell apoptosis in a dose-dependent manner.c-Met/HDAC-IN-2 (0.2-5 μM; 48 hours) significantly causes G2/M-phase arrest in HCT-116 cells in a dose dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备